Previous 10 | Next 10 |
Replimune Group press release ( NASDAQ: REPL ): Q3 GAAP EPS of -$0.69 beats by $0.08 . Cash and cash equivalents of $616.38M For further details see: Replimune Group GAAP EPS of -$0.69 beats by $0.08
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous sq...
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimun...
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), today announced the grant of inducement equity awards to Chris Sarchi, the...
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune’...
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, w...
Summary Today, we revisit an intriguing oncology developmental company called Replimune Group, Inc. for the first time in more than a year. This week the company added drug giant Roche as a developmental partner and addressed its funding needs. Replimune Group stock has staged a nic...
Replimune Group ( NASDAQ: REPL ) has priced its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50/share. Additionally it has priced its public offering of pre-funded warrants to purchase 4.2M shares of its common stock at a purchase price...
Replimune ( NASDAQ: REPL ) on Wednesday announced a proposed public offering of up to $125M of shares and pre-funded warrants. All securities in the offering will be offered by REPL, the company said in a statement . Earlier in the day, REPL announced a collaboration with ...
Replimune Group ( NASDAQ: REPL ), a biotech focused on cancer immunotherapies, announced a collaboration with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) on Wednesday to study combination therapies for colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Per the terms of the ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-14 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...